China Biomanufacturing Innovation

Overview

The emergence of China as a biopharmaceutical innovation hub, evidenced by $130 billion in license-out value in 2025 and landmark multinational partnerships, marking a shift from capacity center to global innovation partner. China's biomanufacturing license-out value reached $130 billion in 2025, signaling the country's transition from a manufacturing capacity center to a global innovation source. The BMS-Henlius $15.2 billion collaboration announced in May 2026 was cited as emblematic of a 'China moment' that panel participants view as sustainable and driven by genuine innovation capability. (Segment 1 (00:00-05:00))